Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
2004 1
2005 3
2006 1
2008 1
2009 1
2010 2
2011 2
2012 3
2014 1
2015 1
2016 2
2017 2
2018 2
2019 1
2020 2
2021 1
2022 3
2023 1
2024 2
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of switching from intravenous to oral antibiotics (amoxicillin-clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial.
Keij FM, Kornelisse RF, Hartwig NG, van der Sluijs-Bens J, van Beek RHT, van Driel A, van Rooij LGM, van Dalen-Vink I, Driessen GJA, Kenter S, von Lindern JS, Eijkemans M, Stam-Stigter GM, Qi H, van den Berg MM, Baartmans MGA, van der Meer-Kappelle LH, Meijssen CB, Norbruis OF, Heidema J, van Rossem MC, den Butter PCP, Allegaert K, Reiss IKM, Tramper-Stranders GA. Keij FM, et al. Among authors: norbruis of. Lancet Child Adolesc Health. 2022 Nov;6(11):799-809. doi: 10.1016/S2352-4642(22)00245-0. Epub 2022 Sep 9. Lancet Child Adolesc Health. 2022. PMID: 36088952 Clinical Trial.
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn's disease: an open-label multicentre randomised controlled trial.
Jongsma MME, Aardoom MA, Cozijnsen MA, van Pieterson M, de Meij T, Groeneweg M, Norbruis OF, Wolters VM, van Wering HM, Hojsak I, Kolho KL, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg-Roord STA, Schreurs MWJ, Rizopoulos D, Doukas M, Escher JC, Samsom JN, de Ridder L. Jongsma MME, et al. Among authors: norbruis of. Gut. 2022 Jan;71(1):34-42. doi: 10.1136/gutjnl-2020-322339. Epub 2020 Dec 31. Gut. 2022. PMID: 33384335 Free PMC article. Clinical Trial.
Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn's disease.
Jongsma MME, Vuijk SA, Cozijnsen MA, van Pieterson M, Norbruis OF, Groeneweg M, Wolters VM, van Wering HM, Hojsak I, Kolho KL, van Wijk MP, Teklenburg-Roord STA, de Meij TGJ, Escher JC, de Ridder L. Jongsma MME, et al. Among authors: norbruis of. Eur J Pediatr. 2022 Aug;181(8):3055-3065. doi: 10.1007/s00431-022-04496-7. Epub 2022 Jun 8. Eur J Pediatr. 2022. PMID: 35672586 Free PMC article.
Infant Milk Formula with Large, Milk Phospholipid-coated Lipid Droplets Enriched in Dairy Lipids Affects Body Mass Index Trajectories and Blood Pressure at School Age: Follow-up of a Randomized Controlled Trial.
Abrahamse-Berkeveld M, Jespers SN, Khoo PC, Rigo V, Peeters SM, van Beek RH, Norbruis OF, Schoen S, Marintcheva-Petrova M, van der Beek EM, Stoelhorst GM, Vandenplas Y, Hokken-Koelega AC; Mercurius Study Group. Abrahamse-Berkeveld M, et al. Among authors: norbruis of. Am J Clin Nutr. 2024 Jan;119(1):87-99. doi: 10.1016/j.ajcnut.2023.10.017. Epub 2023 Nov 15. Am J Clin Nutr. 2024. PMID: 37973475 Free article. Clinical Trial.
Association between duration of intravenous antibiotic administration and early-life microbiota development in late-preterm infants.
Zwittink RD, Renes IB, van Lingen RA, van Zoeren-Grobben D, Konstanti P, Norbruis OF, Martin R, Groot Jebbink LJM, Knol J, Belzer C. Zwittink RD, et al. Among authors: norbruis of. Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):475-483. doi: 10.1007/s10096-018-3193-y. Epub 2018 Jan 24. Eur J Clin Microbiol Infect Dis. 2018. PMID: 29368074 Free PMC article.
The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited.
De Bie CI, Hummel TZ, Kindermann A, Kokke FT, Damen GM, Kneepkens CM, Van Rheenen PF, Schweizer JJ, Hoekstra JH, Norbruis OF, Tjon A Ten WE, Vreugdenhil AC, Deckers-Kocken JM, Gijsbers CF, Escher JC, De Ridder L. De Bie CI, et al. Among authors: norbruis of. Aliment Pharmacol Ther. 2011 Jan;33(2):243-50. doi: 10.1111/j.1365-2036.2010.04507.x. Epub 2010 Nov 14. Aliment Pharmacol Ther. 2011. PMID: 21083595
Etiology of acute gastroenteritis in children requiring hospitalization in the Netherlands.
Friesema IH, de Boer RF, Duizer E, Kortbeek LM, Notermans DW, Norbruis OF, Bezemer DD, van Heerbeek H, van Andel RN, van Enk JG, Fraaij PL, Koopmans MP, Kooistra-Smid AM, van Duynhoven YT. Friesema IH, et al. Among authors: norbruis of. Eur J Clin Microbiol Infect Dis. 2012 Apr;31(4):405-15. doi: 10.1007/s10096-011-1320-0. Epub 2011 Jul 3. Eur J Clin Microbiol Infect Dis. 2012. PMID: 21725865
Randomised clinical trial: First-line infliximab biosimilar is cost-effective compared to conventional treatment in paediatric Crohn's disease.
Vuijk SA, Jongsma MME, Hoeven BM, Cozijnsen MA, van Pieterson M, de Meij TGJ, Norbruis OF, Groeneweg M, Wolters VM, van Wering H, Hummel T, Stapelbroek J, van der Feen C, van Rheenen PF, van Wijk MP, Teklenburg S, Rizopoulos D, Poley MJ, Escher JC, de Ridder L. Vuijk SA, et al. Among authors: norbruis of. Aliment Pharmacol Ther. 2024 Jun;59(12):1510-1520. doi: 10.1111/apt.18000. Epub 2024 Apr 21. Aliment Pharmacol Ther. 2024. PMID: 38644588 Clinical Trial.
28 results